Navigation Links
KV Begins Shipping Evamist(TM) to Wholesalers
Date:4/14/2008

First FDA Approved Estradiol Transdermal Spray Launches KV Into One of

Largest Therapeutic Categories in Women's Healthcare

ST. LOUIS, April 14 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVA, KVB), a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets technology differentiated branded and generic/non-branded prescription pharmaceutical products, announced today that it has initiated launch shipments of Evamist(TM) (estradiol transdermal spray) to wholesalers. Evamist(TM) will be marketed by Ther-Rx Corporation, a division of KV Pharmaceutical. Evamist(TM), indicated for the treatment of moderate-to-severe vasomotor symptoms due to menopause, is a unique transdermal estrogen therapy delivering a low dose of estradiol in a once-daily spray.

The Company believes Evamist(TM) is an outstanding addition to Ther-Rx Corporation's existing women's healthcare portfolio of products, which have been promoted by the Ther-Rx sales force since 1999. The Company anticipates the ability to leverage its strong relationships with Obstetricians/Gynecologists, as well as select primary care physicians, to potentially drive Evamist(TM) to be one of Ther-Rx's largest products in terms of revenue. Evamist(TM) targets an annual $1.3 billion estrogen therapy market where physicians and patients are seeking an effective low-dose estrogen product.

"We're excited about the new opportunity Evamist(TM) brings to the Ther-Rx portfolio and to the women's healthcare market," stated Marc S. Hermelin, KV's Chairman of the Board and Chief Executive Officer. "We believe Evamist(TM) truly differentiates itself from the other products in this category and targets a compelling and im
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. When a Mind Begins to Disappear: A Young Familys Journey to the Dark Side
2. Annual National Public Health Week Begins Today
3. Viscorp, Inc. Announces Name Change to Tianyin Pharmaceutical Co Inc. and Begins Trading Under the Ticker OTC BB: TYNP
4. As Congress Begins Debate on Bush Budget, Front-Line Caregivers Urge Rejection of Medicare Cuts
5. XTend Medical (XMDC) Begins Remote Diabetic Telehealth Program
6. High blood pressure worsening in all states for women; begins to stagnate for men
7. Parental Alienation Awareness Organization Begins Preparations for Parental Alienation Awareness Day - April 25th
8. USA TODAY to Report Special Series "Turning 62: The Retirement Boom Begins"
9. Fitness Begins at Home
10. Work Begins on New Regional Hospital Medical Campus
11. Johnson City Medical Center Begins Offering Einstein Bros. Menu Items at Second On Campus Location
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...ov. 21 The Generic,Pha...ing statement today from,GPhA President and CEO K...ion,(FTC) roundtable on "Emerging Health Care Com...fact that the FTC is conducting this roundtable de...hat consumers have access to safe and,affordable ...
(Date:11/21/2008)... day lead to a novel technique to combat cancer, s...hDay News) -- Belgian researchers have discovered ...sugar for food, and this might lead to new treatme...ive and proliferate, all cells in the body need to...ucose], a process that requires oxygen. Compared w...
(Date:11/21/2008).... 21 NursingCenter.com, the premie...d peer reviewed content, has been,updated to impr...istered,users. Powered by Lippincott Williams &am...over 900 peer-reviewed continuing education activi... than 50 leading nursing journals.,Lippincott Wil...
(Date:11/21/2008)... The general membership of the Med...ee new individuals at their Annual,Awards Dinner ...n New York. A,Lifetime Achievement Award will als...edical Advertising Hall of Fame are: , Ronald P...account position,at Sudler & Hennessey. In 19...
Breaking Medicine News(10 mins):Health News:GPhA Statement on FTC Roundtable on Biogenerics 2Health News:New Approach Keeps Tumor Cells From Refueling 2Health News:NursingCenter.com Launches New Features to Improve User Experience 2Health News:NursingCenter.com Launches New Features to Improve User Experience 3Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 2Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 3
...ttle in Afghanistan are increasingly suffering fro... disorders, say// concerned experts. Ontario’s o...tigation into the matter. It was seen that a cente...dren was caught in a mire of poor funding due to g...
... who had been protesting the alleged manhandling o...third day Friday after Delhi// Health Minister Yog...ecurity would be looked into. "We called off the ... us a written assurance to provide better security...
...lux testing appear in The American Journal of Gast...an College of// Gastroenterology, these guidelines...ease (GERD) diagnostic testing and how they have m...phageal disorders. “Gastroenterologists are confr...
...usting drug remains the most beneficial proven int...an Heart Association.// The Guidelines for the E...o indicate that new options – such as intra-arteri...d mechanical removal of blood clots – show promise...
Other Medicine News:Health News:Collateral Damage-Children Of Canadian Soldiers Suffer 2Health News:Intravenous Delivery of Clot-busting Drug Still Best Intervention for Ischemic Stroke 2
(Date:11/20/2008)... BOSTON, Nov. 20 PAREXE...eading global biopharmaceutical services provider,...ima, Peru to provide regulatory consulting and cli...the Peru office, PAREXEL now has locations through...tin America, which also include Argentina, Brazil,...
(Date:11/19/2008)... , , Study did not achieve statistical si...wswire-FirstCall/ -- Pharmos Corporation (Nasdaq: ... clinical trial of its topical NanoEmulsion (NE) d...nac Diethanolamine. , , The multi-center, r...y evaluated the safety and efficacy of the Company...
(Date:11/19/2008)... -Triggers $5 Million Payment from Roche- , ,... -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY )...nt goal for its Phase 2 trial of R3487/MEM 3454, i...nitive impairment associated with schizophrenia (C...the Phase 2 trial, triggering a $5.0 million payme...
(Date:11/18/2008)... LANSDOWNE, Va., Nov. 18 /PRNewswire-USNewswire/ ...sts gathered at a November national forum to consi...ca,s public health and national economy from outbr...er announced today. , , Among those innovat...on every American kitchen table that detects highl...
Breaking Medicine Technology:PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 342 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Vendormate Again Selected as Top 40 Georgia Innovative Technology Company 13787 1Vendormate Again Selected as Top 40 Georgia Innovative Technology Company 13787 2New TB test means quicker and easier diagnosis for patients 13783 1New TB test means quicker and easier diagnosis for patients 13783 2New TB test means quicker and easier diagnosis for patients 13783 3Curing addiction with cannabis medicines 13779 1Curing addiction with cannabis medicines 13779 2Wandering albatrosses follow their nose 2438 1Wandering albatrosses follow their nose 2438 2
...zixa Shows Dual Activity as Vascular Disrupting Ag...ril 17, 2007—Myriad Genetics, Inc.,(NASDAQ: ....com/">www.myriad.com ) announced today that,it pr...on of its,investigational new drug, Azixa™, ...ing of the American Association for Cancer,Researc...
...NTREAL & MALVERN, Pa.--(BUSINESS WIRE)--Apr 18...of positive preclinical data,from a study of its l...e lymphoblastic leukemia (ALL). The study was disc...g of the American Association,for Cancer Research ...ted potent single agent activity against ALL blast...
Other Medicine Technology:Myriad Genetics Presents Azixa's Mode of Action at AACR 2Myriad Genetics Presents Azixa's Mode of Action at AACR 3Gemin X Presents Positive Preclinical Data of GX15-070 in Infant,ALL at AACR Meeting 2Gemin X Presents Positive Preclinical Data of GX15-070 in Infant,ALL at AACR Meeting 3
...arefully considered with both the practitioner and...ptimum viewing angle and the largest field of view...r perfect focus where it is needed - in the eye - ... light beam and infinity focus, ensures that whate...
The Beta 200S combines Heine's patented aspherical optics (U.S. Pat. 4.963.014) and a single-step Rekoss disk with a range of 36 to +38 dpt. to provide perfectly-focused images even in cases of high
The Heine Beta 200S is the first hand-held direct ophthalmoscope with a combination of patented aspherical optics (U.S. Pat. 4.963.014) and a range of corrective lenses from 36 to +38 dpt. in single
...ptics. Includes XHL halogen bulb. The separation o...e aspherical optical system avoids corneal and iri...ws you to view the whole of the illuminated sectio...nal ophthalmoscopes often let you see only part of...
Medicine Products: